Navigation Links
July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia

onia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).

For important information regarding the safety and use of ANTARA, please see the full prescribing information available at www.antararx.com.

Important Safety Information about FACTIVE Tablets

In clinical trials, the most common (more than 2% incidence) side effects reported in patients receiving FACTIVE versus comparators were diarrhea (5.0% vs. 6.2%), rash (3.5% vs. 1.1%), nausea (3.7% vs. 4.5%), headache (4.2% vs. 5.2%), abdominal pain (2.2% vs. 2.2%), vomiting (1.6% vs. 2.0%), and dizziness (1.7% vs. 2.6%). In clinical trials, drug-related rash was reported in 2.7% of patients receiving gemifloxacin and was more commonly observed in patients less than 40 years of age, especially females. The incidence of rash increases with treatment longer than the maximum-labeled duration of 7 days. In clinical trials, the discontinuation rate due to drug-related adverse events was similar for FACTIVE tablets and comparators (2.2% versus 2.1%, respectively).

FACTIVE is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product components. Patients receiving marketed fluoroquinolones have reported serious and occasionally fatal hypersensitivity and/or anaphylactic reactions, peripheral neuropathy, antibiotic-associated colitis and tendon ruptures. FACTIVE should be discontinued immediately at the first sign of any of these events.

Fluoroquinolones may prolong the QT interval in some patients. FACTIVE should be avoided in patients with a history of prolongation of the QTc interval, patients with uncorrected electrolyte disorders (hypokalemia or hypomagnesemia), and patients receiving Class IA or Class III antiarrhythmic agents. In clinical studies with gemifloxacin, CNS effect
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. FDA Issues Safety Alert on Avandia
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
7. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/16/2008)...resentations at ASCO Annual Meeting Will Further D... in Front-line Multiple Myeloma -, CAMBRIDGE, Mas...als,The Takeda Oncology Company, today announced ...heduled to be featured at the 2008 American Societ...icago, Illinois, May 30 -,June 3, 2008. The data w...
(Date:5/16/2008)...akers include industry and customer thought leader... Inc., the recognized,leader and trusted resource ...sted a constellation of prestigious academic medic...tners at its annual user group meeting in San,Fran... to internally and,collaboratively manage thousand...
(Date:5/16/2008)... Include:, -- Results demonstrating that TYKERB a...eaningful extension of progression-free survival (...ck both the inside and,outside of the HER2 recepto...ta demonstrating activity of TYKERB alone despite ...f trastuzumab and chemotherapy, LONDON and PHILAD...
(Date:5/16/2008)....J., May 16 /- Veridex, LLC announced... Corporation of America Holdings,(LabCorp), has co...r,prostate cancer. The new assay uses the biologic...ncer, detecting the methylation of the gene,GST-Pi... primarily in,cancer. Veridex is developing the me...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 1Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 1Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 3Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 1Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 2Clues to ancestral origin of placenta emerge in Stanford study 2886 1Clues to ancestral origin of placenta emerge in Stanford study 2886 2Clues to ancestral origin of placenta emerge in Stanford study 2886 3
(Date:5/17/2008)...ampaign on Behalf of CSL Behring, maker of Zema...ntation Therapy, K...a Biggs, a fashion,designer and actress who appear... an education campaign on behalf of CSL Behring, a...ntitrypsin (AAT) deficiency,after her own diagnosi...
(Date:5/16/2008)... Law Offices of Howard G. Smith,announces a June 9... the,securities class action lawsuit filed on beha...red the common stock of Inverness Medical,Innovati...Amex: IMA ) in the,Company,s secondary public off...riod"). The shareholder lawsuit is pending in the ...
(Date:5/16/2008)...critics want agency to act, not wait years , ...o-consumer drug ads on television should include a... to report adverse side effects, U.S. health exper...anel that advises the U.S. Food and Drug Administr...the FDA for print ads. At Friday,s meeting, the pa...
(Date:5/16/2008)..., WASHINGTON, May 16 /PRNewswire-USNewswire/ -- M...nicians in the Greater Portland, Oregon and,Vancou...r contract as,Teamsters., "The Teamsters are plea... contract that gives them job protection and a sec...sident Jim Hoffa., The workers, both full-time an...
Breaking Medicine News(10 mins):Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
...k of developing motor neurone disease can be reduc... high in polyunsaturated fat// or vitamin E, accor... fat included both omega-6 fat found abundantly in...n oil and omega 3 fat found in fish and nuts, repo...
...an attempt to assess and ensure health of children...tests to monitor children's growth//, motor develo...by the World Health Organization. It is hoped tha...lth care workers to take appropriate measures to e...
...attendant of a patient in an emergency ward of the... junior resident on duty//, alleging that the doct...his fiancé’s check-up. This allegation has been to.... Immediately a strike ensued by the Doctors at G...
... obese may just have a succor to turn to for help ...dy, injections of the gut hormone oxyntomodulin ma...identally, Oxyntomodulin is generated by the body,... feelings of satiation, or Feeling Full. Steve Bl...
Other Medicine News:Health News:Polyunsaturated Fat, Vitamin E Lowers Risk Of Motor Neurone Disease 2Health News:Childhood Obesity Vs Malnutrition- A Spotlight On WHO Obesity Measurement For Kids 2Health News:Childhood Obesity Vs Malnutrition- A Spotlight On WHO Obesity Measurement For Kids 3Health News:Hormone - A Shot in the Arm for Weight Loss 2
...ected curve trial lenses are ground with the same ...nd are invaluable in treating low vision patients....rs contain a disproportionately large number of le... to produce, and fewer lenses in the higher power ...
simplified focusing guidance system has made the LM-770 the easiest instrument to use of its type. Technicians can be trained to operate the LM-770 with a minimum of instruction. The instrument tells
...on electronic refractor to its line of Vision Diag...ce of a wireless, infrared remote control and is p...s. The Evolution gives the practitioner complete c...eld remote control. With the Evolution, the practi...
Marco Radiusgauges are available with either a standard or digital display as well as in either monocular or binocular form. All offer the functions of two instruments in one, measuring both the curv
Medicine Products: